Moreover, given the ability of IL-32 to induce a T cell–inflamed TME, it potentiated the response to anti–PD-1 therapy and strongly correlated with response to pembrolizumab and nivolumab in patients with melanoma. This evidence concerns the gene IL32 and melanoma.